China Life's H1 Net Profit Surges 228%, Plans to Boost AI and Biotech Investments
Nashnova编辑部
China Life (02628) posted a record 228% jump in first-half net profit to RMB 134.5 billion, and management flagged AI, semiconductors, and biotech as the next investment priorities — marking a strategic pivot for the world's largest life insurer by market cap.
Profit more than tripled — where did the money come from?
First-half revenue hit RMB 434.3 billion, up 81.5% year-on-year; net profit reached RMB 134.5 billion, up 228% — both all-time highs.
The company credited four drivers: balanced growth and risk control, product diversification, refined asset allocation, and steady investment returns.
This means → the surge was not a one-trick result; both the underwriting side and the investment side fired together — the "dual-engine" outcome insurers aim for.
Why is management suddenly pivoting toward tech?
Vice President Liu Hui told a Beijing press conference: "Investing in sectors tied to new-quality productive forces is the core growth driver most likely to deliver differentiated returns."
He disclosed that the portfolio already includes CXMT (Chang Xin Memory Technologies, a leading Chinese memory-chip maker), and that the next wave of deployment will target AI, semiconductors, healthcare, biotech, and next-generation infrastructure.
In plain terms = a trillion-yuan insurer that has lived on government bonds and fixed income is now steering a share of its capital toward chips and biologics — a strategic-level allocation shift.
What should the market make of this signal?
China Life is the world's largest life insurer by market cap, dual-listed in Shanghai and Hong Kong; its allocation decisions set the tone for the broader insurance-capital sector.
This reflects a deeper force: with interest rates low, traditional fixed-income returns are being compressed, and mega-insurers must look to high-growth sectors for yield.
The key checkpoint: whether this strategic signal translates into quantifiable exposure in the second half — the market needs to see actual deployment, not just directional rhetoric at a press conference.
市场有风险，内容仅供研究参考，不构成投资建议。